Literature DB >> 7363402

Phase I study of ethylbis(2,2-dimethyl-1-aziridinyl) phosphinate (AB-163).

G L Wampler, M Kuperminc, W Regelson.   

Abstract

Ethylbis(2,2-dimethyl-1-aziridinyl)phosphinate (AB-163) was used to treat 27 patients in a phase I trial. The limiting toxicity on a weekly schedule of IV administration involved nausea and vomiting associated with a variety of cholinergic side effects, including possible seizures. A starting dose of 300--400 mg/M2/week is suggested for a Phase II trial. One partial response in a patient with squamous-cell carcinoma of the cervix metastatic to the lungs was seen.

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7363402     DOI： 10.1007/bf00255459

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  10 in total

1.  THE EFFECT OF RADIATION ON SPLENOMEGALY INDUCED BY THE FRIEND LEUKEMIA VIRUS AND ITS MODIFICATION BY ETHY-N-BIS(2,2-DIMETHYL-ETHYLAMIDINOPHOSPHORO)-CARBAMATE (AB-132), ACTINOMYCIN D, AND AET.

Authors:  W REGELSON; O PIERUCCI
Journal:  Radiat Res       Date:  1964-06       Impact factor: 2.841

2.  Consideration of chemical reaction mechanisms in relationship to the biological action of "dual antagonists".

Authors:  T J BARDOS
Journal:  Biochem Pharmacol       Date:  1962-03       Impact factor: 5.858

3.  Dual antagonists; alkyl N-(bis-(ethylenimido) phosphoro)-carbamates; a new series of anti-tumour agents.

Authors:  T J BARDOS; Z B PAPANASTASSIOU; A SEGALOFF; J L AMBRUS
Journal:  Nature       Date:  1959-02-07       Impact factor: 49.962

4.  Synthesis and chemotherapeutic effects of ethyl bis-(2,2-dimethyl)-ethylenamido phosphate. A preliminary report.

Authors:  Z F Chmielewicz; T J Bardos; A Munson; H L Babbitt; J L Ambrus
Journal:  J Pharm Sci       Date:  1967-09       Impact factor: 3.534

5.  Combination radiotherapy and chemotherapy for P388 lymphocytic leukemia in vivo.

Authors:  I Wodinsky; J Swiniarski; C J Kensler; J M Venditti
Journal:  Cancer Chemother Rep 2       Date:  1974-03

6.  Combination of chemotherapy with dual antagonists and radiotherapy in the treatment of neoplastic disease.

Authors:  T J Bardos; J L Ambrus; C M Ambrus
Journal:  J Surg Oncol       Date:  1971       Impact factor: 3.454

7.  Chemical mechanism of the radiation potentiating effects of 2,2-dimethylaziridine-type antitumor agents.

Authors:  T J Bardos; J A Dunn; M E Perlman
Journal:  Int J Radiat Oncol Biol Phys       Date:  1979-09       Impact factor: 7.038

8.  Absence of cross-resistance to alkylating agents in cyclophosphamide-resistant L1210 leukemia.

Authors:  G L Wampler; W Regelson; T J Bardos
Journal:  Eur J Cancer       Date:  1978-09       Impact factor: 9.162

9.  Radiation potentiating effect of ethyl bis(2,2-dimethyl-1-aziridinyl) phosphinate (AB-163).

Authors:  G L Wampler; J A Wassum; R Belgrad
Journal:  Int J Radiat Oncol Biol Phys       Date:  1979-09       Impact factor: 7.038

10.  Studies on the chemistry, antitumor activity, and pharmacology of ethyl di-(2,2-dimethyl)ethylenamido phosphate (AB-163).

Authors:  A E Munson; H Babbitt; Z F Chmielewicz; T J Bardos; J L Ambrus
Journal:  J Surg Oncol       Date:  1969       Impact factor: 3.454
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.